Invest now
Shilpa Medicare share price
High risk
You have to be logged in to add this to Watchlist.- ₹963.00(2.42%)September 11, 2026 15:29:55 PM IST
- NSE
- BSE
- Vol : 1.57 M (NSE + BSE)Last 20 day avg : 1.33 M
Shilpa Medicare is trading 2.42% upper at Rs 963.00 as compared to its last closing price. Shilpa Medicare has been trading in the price range of 974.50 & 910.05. Shilpa Medicare has given 192.67% in this year & -1.70% in the last 5 days. Shilpa Medicare has TTM P/E ratio 47.92 as compared to the sector P/E of 37.04.There are 4 analysts who have initiated coverage on Shilpa Medicare. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 100.89 Crores in its last quarter.Listed peers of Shilpa Medicare include Sun Pharmaceutical Industries (-1.18%), Divi's Laboratories (-0.84%), Torrent Pharmaceuticals (0.95%).The Mutual Fund holding in Shilpa Medicare was at 4.21% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Shilpa Medicare was at 11.39% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 12 Sep 2026, 01:36 PM IST
- BetaLow volatility0.54Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.25The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.06Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation11.51The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Shilpa Medicare News
Shilpa Medicare Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,842.00 | -1.18 | 4,41,947.09 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,326.00 | -0.84 | 2,47,576.00 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,975.00 | 0.95 | 1,89,226.24 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,365.00 | -1.09 | 1,10,272.68 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,119.50 | 0.13 | 1,11,670.56 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allShilpa Medicare Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-05 | Quarterly Results |
| 2026-05-22 | Audited Results & Dividend |
| 2026-02-06 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-13 | Quarterly Results |
About the company Shilpa Medicare
- IndustryBiotechnology & Drugs
- ISININE790G01031
- BSE Code530549
- NSE CodeSHILPAMED
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
Shilpa Medicare Share Price FAQs
Shilpa Medicare is trading at 963.00 as on Fri Sep 11 2026 09:59:55. This is 2.42% upper as compared to its previous closing price of 940.25.
The market capitalization of Shilpa Medicare is 18759.71 Cr as on Fri Sep 11 2026 09:59:55.
The average broker rating on Shilpa Medicare is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Shilpa Medicare is 980.65 whereas the 52 wk low is 260.00
Shilpa Medicare can be analyzed on the following key metrics -
- TTM P/E: 47.92
- Sector P/E: 37.04
- Dividend Yield: 0.06%
- D/E ratio: -
Shilpa Medicare reported a net profit of 243.33 Cr in 2026.
The Mutual Fund Shareholding was 4.21% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Shilpa Medicare QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.